Abstract
Introduction
Low Molecular Weight Heparins (LMWHs) and Fondaparinux have been widely used as anticoagulants. Mass prescription may lead to prescriptive inappropriateness, which causes Heparin-induced thrombocytopenia and other side effects.
Objectives
The study investigates the appropriate prescription of LMWHs and Fondaparinux in Tuscany. We aim to validate the crude measure of prescription appropriateness of the Key Performance Indicator (KPI) “Patients treated with LMWHs and Fondaparinux every hundred residents in Tuscany” as a proxy for monitoring prescription appropriateness.
Methods
To compare a crude KPI based only on drug consumption with a refined KPI based on exclusions listed in the clinical guidelines, a retrospective observational cohort study was carried out, using the RECORD guidelines for the year 2019. The refined indicator is computed via record linkage of different datasets regarding (a) pharmaceutical services; (b) hospital discharge records; (c) outpatient services; and (d) birth certificates. We apply exclusion criteria to identify the cohort of patients. Values of the KPI are compared, by ranking, with those obtained from its refined version. A Spearman test was performed to validate the use of the crude KPI as a proxy.
Results
208,717 LMWH and Fondaparinux users are identified, of which 103,299 fall within the study’s inclusion criteria. 16,817 (16%) of LMWHs and Fondaparinux users are classified as high consumption. The refined version of the KPI produces the same ranking results in terms of local health districts (rho = 0.98 p<0.01).
Conclusions
Although the crude KPI is less refined and detailed than the adjusted indicator computed by our study, it has proven capable to provide an accurate snapshot of the use of these drugs across the region. This analysis is useful to enable regional and local managers to run rapid and simple indicators to monitor the appropriateness of LMWHs and Fondaparinux. This analysis should be reviewed periodically to confirm its accuracy.
Publisher
Public Library of Science (PLoS)
Reference43 articles.
1. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke;PA Sandercock;Cochrane Database of Systematic Reviews,2017
2. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke;DL Gordon;Clin Neuropharmacol,1990
3. Low Molecular Weight Heparin: Biochemistry, Pharmacology, Perioperative Prophylaxis Regimens, and Guidelines for Regional Anesthetic Management.;TT Horlocker;Anesth Analg.,1997
4. LOW-MOLECULAR-W EIGHT HEPARINS;Weitz Jeffrey;N Engl J Med,1997
5. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins.;E Young;Thromb Haemost,1993
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献